The Mayo Clinic has maintained excellence in providing broad based multidisciplinary medical care to an increasing annual population of patients over the past 80 years. A large percentage of patients who are evaluated each year are diagnosed as having newly identified malignancies. An additional large group of patients seek medical care for malignant disease diagnosed in other medical practices. Many of this overall group of cancer patients are placed on clinical investigational research protocols. These programs include not only Mayo Clinic based research programs but also a number of important research programs conducted through the cooperative program of the Eastern Cooperative Oncology Group. The specific objective of this project is that of participation in ECOG activities directed at improved patient care and an increased understanding of the complexities of and management treatment programs for various cancer problems. Our participation would include efforts to improve diagnostic procedures, the further exploration of single and multimodal treatment programs, clinical pharmacologic research of new anticancer agents, and patient involvement in appropriate epidemiologic programs. Our past scientific participation in ECOG activities has been significant and will be continued in our multiple areas of interest. Patient entry to the broad spectrum of research programs will continue to be provided through expanded Mayo and NCCTG affiliate participation. The quality of data and our research involvement as has been demonstrated by our past record in ECOG activities will continue to be a primary Mayo Clinic requirement.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013650-15
Application #
3556219
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1989-04-30
Budget Start
1987-05-01
Budget End
1988-04-30
Support Year
15
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 159 publications